Cytokinetics (CYTK) was initiated by Citi analysts with a Buy rating, citing potential FDA approval for its lead asset ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cytokinetics (CYTK – Research Report) and ...

Citi initiated coverage of Cytokinetics (CYTK) with a Buy rating and $86 price target. The shares seem attractive at current levels, given the ...

JMP Securities reiterated its Market Outperform rating and $78.00 price target for Cytokinetics shares (NASDAQ:CYTK). This affirmation comes despite the stock experiencing a significant drop on ...

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is ...

Cytokinetics , Inc. (NASDAQ:CYTK), with a market capitalization of $5.65 billion, is approaching a pivotal moment in its journey to become a leading player in the cardiovascular therapeutics market.

Sage Therapeutics was in focus after it rejected Biogen's acquisition proposal. Sage Therapeutics stock gained after it announced that its board of directors has rejected the unsolicited, non-binding ...

SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the ...

Inspire Investing LLC boosted its position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 7.8% in the ...

We recently published a list of 10 Stocks That Analysts Are Talking About. In this article, we are going to take a look at ...

Like any other informed investor, we are always on the hunt for stocks that analysts are talking about. Analysts use their in ...